Pharmaceuticals

biote Corp.

biote Corp. released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 44.94 M (forecast USD 46.02 M), actual EPS USD 0.0599 (forecast USD 0.0366)

biote Corp. to Release FY2026 Q1 Earnings on May 6 After-Market (EST), Forecast Revenue USD 46.02 M, EPS USD 0.0366

biote Corp. released FY2025 earnings on March 11 After-Market EST, actual revenue USD 192.22 M (forecast USD 191.65 M), actual EPS USD 0.74 (forecast USD 0.66)

biote Corp. released FY2025 Q4 earnings on March 11 After-Market EST, actual revenue USD 46.41 M (forecast USD 45.79 M), actual EPS USD 0.0599 (forecast USD 0.02)

biote Corp. to Release FY2025 Q4 Earnings on March 11 After-Market (EST), Forecast Revenue USD 45.79M, EPS USD 0.02

biote Corp. released FY2025 9 Months Earnings on November 5 After-Market EST, actual revenue USD 145.81 M, actual EPS USD 0.6899

biote Corp. released FY2025 Q3 earnings on November 5 After-Market (EST), actual revenue USD 47.96 M (forecast USD 47.76 M), actual EPS USD 0.22 (forecast USD 0.0466)

biote Corp. to Release FY2025 Q3 Earnings on November 5 After-Market (EST), Forecast Revenue USD 47.76 M, EPS USD 0.0466

biote Corp. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 48.86 M (forecast USD 49.54 M), actual EPS USD 0.0999 (forecast USD 0.0633)

biote Corp. released FY2025 Semi-Annual Earnings on August 6 After-Market EST, Actual Revenue USD 97.86 M, Actual EPS USD 0.4599

biote Corp. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 49.54 M, EPS USD 0.0633

BIOTE Corp Appoints New Board Member

Guines LLC Reports Acquisition of biote Corporation Common Stock

Biote Corp. released FY2025 Q1 earnings on May 7 After-Market EST, actual revenue USD 48.99 M (forecast USD 47.25 M), actual EPS USD 0.37 (forecast USD 0.065)

biote Corp. Reports First Quarter Revenues Exceeding Estimates

Biote Corp Expected to Report 7 Cent Earnings Per Share for Q1 2025

Guines LLC reports acquisition of biote Corporation stock

biote Corp. to release FY2025 Q1 earnings on May 7 After-Market EST, forecast revenue USD 47.25 M, EPS USD 0.065

Andrew R. Heyer Acquires 75,000 Shares of Class A Common Stock of biote Corp. for $296,042 on March 17, 2025

Executives of biote Corp. made significant stock purchases on March 17, 2025

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

Micware

Silexion Therapeutics

GCL Global

MetaVia

Vida Global

MicroAlgo

BiomX

BTMD

Biote Corp. held its 2026 annual meeting, where shareholders elected Andrew R. Heyer and Dana Jacoby as Class I directors until 2029. They also ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026. The latest analyst rating for BTMD stock is a Buy with a $3.00 price target, though it faces financial risks due to negative equity and debt.

Tip Ranks

biote shareholders elect directors and ratify Deloitte appointment

Earnings Watch

biote Corp. | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 44.94 M

biote Corp. | 10-K: FY2025 Revenue Beats Estimate at USD 192.22 M

biote Corp. (NASDAQ:BTMD) shares fell 0.9% to $2.22 during mid-day trading, with a volume decline of 52% from the average. Analysts have mixed ratings, with Weiss Ratings issuing a 'sell' and Truist Financial a 'buy' with a price target of $4.00. The stock has a consensus rating of 'Hold' and a target price of $2.75. The company reported $46.41 million in revenue and $0.06 EPS for the last quarter, exceeding estimates. Institutional investors hold 21.68% of the stock, reflecting growing interest in the hormone optimization market.

Market Beat

Truist Financial

Toronto Dominion Bank

State Street

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

State Street® US Equity Premium Inc ETF

biote (NASDAQ:BTMD) Trading Down 0.9%  - What's Next?

ABCL

SBIO

IBBQ

ERNA

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NRXBF Stock News

StockTitan

Abcellera Biologics

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Adma Biologics

Invesco Nasdaq Biotechnology ETF

VG Health

Ernexa Therapeutics

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

Health Care Select Sector SPDR

iShares Biotechnology ETF

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NRXBF Stock News

Biote's April 2026 investor presentation revealed 2025 revenue of $192.2M and adjusted EBITDA of $53.5M, with a 27.8% margin. The company reported over 9,200 certified practitioners and approximately 400,000 active patients as of December 31, 2025. Capital allocation actions included a $25.1M repurchase of 5.5M Class V shares and other settlements totaling $31M. For 2026, Biote aims to expand practitioner onboarding, enhance clinical decision support software, and develop higher-value offerings to drive growth.

TradingView

Biote posts April 2026 investor presentation highlighting $192.2M 2025 revenue and $53.5M Adj. EBITDA

NBSE.ESC

BTAI

MindBio Therapeutics Corp. has successfully closed a private placement, raising $1,437,828.87 by issuing 2,396,381 units at $0.60 each. The funds will be used to enhance the development of its intoxication detection technology. Additionally, the company has engaged two service providers for promotional and marketing services to increase public awareness and investor reach. The engagements include cash compensation and will run for one year. All securities issued are subject to resale restrictions for four months and are pending final regulatory approvals.

The newswire.ca

ESC NEUBASE THERAPEUTI

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Mustang Bio

Pasithea Therapeutics

Bioxcel Therap

MindBio Announces Closing of Private Placement

MindBio Therapeutics Corp. has announced an increase in its non-brokered private placement from $650,000 to up to $1.5 million. The company plans to issue up to 2.5 million units at $0.60 each, with each unit consisting of one common share and one warrant. The warrants allow for the purchase of additional shares at $0.80 for 36 months. The offering is subject to regulatory approvals and will include finders' fees for eligible third parties. All securities will have a four-month resale restriction.

Proshares UltraShort Nasdaq Biotech

MindBio Announces Upsize to Private Placement up to $1.5 Million

biote Corp.(BTMD.US)

biote shareholders elect directors and ratify Deloitte appointment

biote Corp. | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 44.94 M

biote Corp. | 10-K: FY2025 Revenue Beats Estimate at USD 192.22 M

biote (NASDAQ:BTMD) Trading Down 0.9% - What's Next?

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization | NRXBF Stock News

Biote posts April 2026 investor presentation highlighting $192.2M 2025 revenue and $53.5M Adj. EBITDA

MindBio Announces Closing of Private Placement

MindBio Announces Upsize to Private Placement up to $1.5 Million